Biogen

News

Sage sues Biogen after unsolicited takeover bid

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.

News

FDA sets August date for subcutaneous Leqembi decision

FDA has started its review of an autoinjector version of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to be dosed at home.

News

Biogen offers to buy out wilting Sage for $442 million

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.

News

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on

News

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t

News

Australia joins EU in turning down Alzheimer's drug Leqembi

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

Sage sues Biogen after unsolicited takeover bid

FDA sets August date for subcutaneous Leqembi decision

Biogen offers to buy out wilting Sage for $442 million

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Biogen shows its IgAN hand with felzartamab data

Australia joins EU in turning down Alzheimer's drug Leqembi

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks